Kalaris Therapeutics Inc.

02/17/2026 | Press release | Distributed by Public on 02/17/2026 19:16

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
AKKARAJU SRINIVAS
2. Issuer Name and Ticker or Trading Symbol
Kalaris Therapeutics, Inc. [KLRS]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
C/O SAMSARA BIOCAPITAL, LLC, 628 MIDDLEFIELD ROAD
3. Date of Earliest Transaction (Month/Day/Year)
12/18/2025
(Street)
PALO ALTO, CA 94301
4. If Amendment, Date Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/18/2025 P(1) 479,847 A $10.42 1,979,847(2) I By Samsara Opportunity Fund, L.P.(3)
Common Stock 10,968,234(4) I By Samsara BioCapital, L.P.(5)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
AKKARAJU SRINIVAS
C/O SAMSARA BIOCAPITAL, LLC
628 MIDDLEFIELD ROAD
PALO ALTO, CA 94301
X X
Samsara BioCapital, L.P.
C/O SAMSARA BIOCAPITAL, LLC
628 MIDDLEFIELD ROAD
PALO ALTO, CA 94301
X
Samsara BioCapital GP, LLC
C/O SAMSARA BIOCAPITAL, LLC
628 MIDDLEFIELD ROAD
PALO ALTO, CA 94301
X
Samsara Opportunity Fund, L.P.
C/O SAMSARA BIOCAPITAL, LLC
628 MIDDLEFIELD ROAD
PALO ALTO, CA 94301
X
Samsara Opportunity Fund GP, LLC
C/O SAMSARA BIOCAPITAL, LLC
628 MIDDLEFIELD ROAD
PALO ALTO, CA 94301
X

Signatures

/s/ Srinivas Akkaraju 02/17/2026
**Signature of Reporting Person Date
Samsara BioCapital, L.P., By: Samsara BioCapital GP, LLC, its General Partner, By /s/ Srinivas Akkaraju, Managing Member 02/17/2026
**Signature of Reporting Person Date
Samsara BioCapital GP, LLC, By /s/ Srinivas Akkaraju, Managing Member 02/17/2026
**Signature of Reporting Person Date
Samsara Opportunity Fund, L.P., By Samsara Opportunity Fund GP, LLC, its General Partner, By /s/ Srinivas Akkaraju, Managing Member 02/17/2026
**Signature of Reporting Person Date
Samsara Opportunity Fund GP, LLC, By /s/ Srinivas Akkaraju, Managing Member 02/17/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction.
(2) Represents the number of shares held as of the date of this filing, including the shares purchased by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund") on December 22, 2025, as reported in the reporting persons' Form 4 filed with the SEC on December 22, 2025 (the "Prior Report"). The Prior Report is deemed amended hereby.
(3) Securities are directly held by Samsara Opportunity Fund. Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.
(4) The shares held by Samsara LP reflects the disposition of 479,847 shares, to Samsara Opportunity Fund as described in footnote (1), in which the Reporting Person had no pecuniary interest. The transfer of such shares by Samsara LP did not involve a change in the Reporting Person's beneficial ownership of such shares and, accordingly, was exempt from reporting under Section 16.
(5) Shares held by Samsara LP. The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Kalaris Therapeutics Inc. published this content on February 17, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on February 18, 2026 at 01:16 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]